R&D
Cardiovascular disease today: NMR-based lipoprotein profilin...
pharmaphorum spoke with Andreas Wolf, chief technology officer at numares Health about NMR-based lipoprotein profiling and cardiovascular disease.
News
UK biotech financing shoots up, setting up "a record year"
UK biotech shrugged off a difficult economic environment with a 44% increase in venture capital investment in the third quarter to £270m, says BIA.
News
ESMO26: Roche's KRAS drug tops approved drugs in NSCLC
In the Krascedo-1 trial, Roche's KRAS G12C inhibitor divarasib met high expectations, with a head-to-head win over Lumakras and Krazati.
News
ESMO26: Sac-TMT delivers the goods in PD-L1-negative NSCLC
Kelun and MSD's TROP2-directed ADC, sac-TMT, reduced the risk of disease progression or death by 51% when used first-line in PD-L1-negative NSCLC.
News
ESMO26: Bayer's Nubeqa finds new prostate cancer role
Bayer's prostate cancer drug Nubeqa has reduced the risk of the disease spreading or death by 58% in patients at high risk of disease recurrence.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
